PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations

Cancer Biology and Therapy

Volumn 17, Issue 4, 2016, Pages 407-413

  Ji, Mei ^a,b   Liu, Yan ^a   Li, Qing ^a   Li, Xiaodong ^a,b   Ning, Zhonghua ^a   Zhao, Weiqing ^a   Shi, Hongbing ^a   Jiang, Jingting ^a,b   Wu, Changping ^a,b  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Jiangsu Engineering Research Center for Tumor Immunotherapy   (China)

Author keywords

EGFR; KRAS; non small cell lung cancer; PD 1; PD L1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PDCD1 PROTEIN, HUMAN; PROTEIN P21;

ADULT; ARTICLE; CANCER PATIENT; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 84962115509     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1156256     Document Type: Article

References (46)

1. R.Siegel, D.Naishadham, A.Jemal. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
2. B.W.Stewart, C.P.Wild. World Cancer Report 2014. Lyon: International Agency for Research on Cancer, 2014.
3. W.Xu, G.Yang, Y.Xu, Q.Zhang, Q.Fu, J.Yu, M.Yu, W.Zhao, Z.Yang, F.Hu, et al. The possibility of traditional chinese medicine as maintenance therapy for advanced nonsmall cell lung cancer. Evid Based Complement Alternat Med 2014; 2014:278917; PMID:25165478; http://dx.doi.org/10.1155/2014/278917
4. K.Kobayashi, K.Hagiwara. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol 2013; 8:27-33; PMID:23361373; http://dx.doi.org/10.1007/s11523-013-0258-9
5. C.G.Azzoli, S.Temin, G.Giaccone. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract 2012; 8:63-6; PMID:22548014; http://dx.doi.org/10.1200/JOP.2011.000374
6. R.I.Nicholson, J.M.Gee, M.E.Harper. EGFR and cancer prognosis. Eur J Cancer 2001; 37 Suppl 4:S9-15; PMID:11597399; http://dx.doi.org/10.1016/S0959-8049(01)00231-3
7. T.J.Lynch, D.W.Bell, R.Sordella, S.Gurubhagavatula, R.A.Okimoto, B.W.Brannigan, P.L.Harris, S.M.Haserlat, J.G.Supko, F.G.Haluska, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39; PMID:15118073; http://dx.doi.org/10.1056/NEJMoa040938
8. J.G.Paez, P.A.Janne, J.C.Lee, S.Tracy, H.Greulich, S.Gabriel, P.Herman, F.J.Kaye, N.Lindeman, T.J.Boggon, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500; PMID:15118125; http://dx.doi.org/10.1126/science.1099314
9. W.Pao, V.Miller, M.Zakowski, J.Doherty, K.Politi, I.Sarkaria, B.Singh, R.Heelan, V.Rusch, L.Fulton, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-11; PMID:15329413; http://dx.doi.org/10.1073/pnas.0405220101
10. D.A.Eberhard, B.E.Johnson, L.C.Amler, A.D.Goddard, S.L.Heldens, R.S.Herbst, W.L.Ince, P.A.Jänne, T.Januario, D.H.Johnson, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900-9; PMID:16043828; http://dx.doi.org/10.1200/JCO.2005.02.857
11. K.Schmid, N.Oehl, F.Wrba, R.Pirker, C.Pirker, M.Filipits. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009; 15:4554-60; PMID:19584155; http://dx.doi.org/10.1158/1078-0432.CCR-09-0089
12. D.M.Zaiss, J.van Loosdregt, A.Gorlani, C.P.Bekker, A.Grone, M.Sibilia, P.M.van Bergen en Henegouwen, R.C.Roovers, P.J.Coffer, A.J.Sijts. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 2013; 38:275-84; PMID:23333074; http://dx.doi.org/10.1016/j.immuni.2012.09.023
13. A.Pivarcsi, A.Muller, A.Hippe, J.Rieker, A.van Lierop, M.Steinhoff, S.Seeliger, R.Kubitza, U.Pippirs, S.Meller, et al. Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A 2007; 104:19055-60; PMID:18025475; http://dx.doi.org/10.1073/pnas.0705673104
14. A.M.Intlekofer, C.B.Thompson. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 2013; 94:25-39; PMID:23625198; http://dx.doi.org/10.1189/jlb.1212621
15. Y.Zhang, S.Huang, D.Gong, Y.Qin, Q.Shen. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010; 7:389-95; PMID:20514052; http://dx.doi.org/10.1038/cmi.2010.28
16. K.Hirahara, K.Ghoreschi, X.P.Yang, H.Takahashi, A.Laurence, G.Vahedi, G.Sciumè, A.O.Hall, C.D.Dupont, L.M.Francisco, et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 2012; 36:1017-30; PMID:22726954; http://dx.doi.org/10.1016/j.immuni.2012.03.024
17. J.Konishi, K.Yamazaki, M.Azuma, I.Kinoshita, H.Dosaka-Akita, M.Nishimura. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10:5094-100; PMID:15297412
18. C.Y.Mu, J.A.Huang, Y.Chen, C.Chen, X.G.Zhang. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28:682-8; PMID:20373055; http://dx.doi.org/10.1007/s12032-010-9515-2
19. S.J.Wolfle, J.Strebovsky, H.Bartz, A.Sahr, C.Arnold, C.Kaiser, A.H.Dalpke, K.Heeg. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 2011; 41:413-24; PMID:21268011; http://dx.doi.org/10.1002/eji.201040979
20. J.Brahmer. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and longterm safety in a phase 1 trial. Presented at: IASLC 15th World Conference on Lung Cancer; October 2013; Sydney, Australia. MO18.03.
21. J.Sosman, M.Sznol, D.McDermott, R.Carvsjal, D.Lawrence, S.L.Topalian, et al. Clinical activity and safety of anti-programmed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (PTS) with advanced melanoma (MEL) in ESMO. 2012.
22. N.Rizvi. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013; 31(suppl; abstr 8072); 3935-43; PMID:24043745
23. O.Hamid, C.Robert, A.Daud, F.S.Hodi, W.J.Hwu, R.Kefford, J.D.Wolchok, P.Hersey, R.W.Joseph, J.S.Weber, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
24. J.R.Brahmer, S.S.Tykodi, L.Q.Chow, W.J.Hwu, S.L.Topalian, P.Hwu, C.G.Drake, L.H.Camacho, J.Kauh, K.Odunsi, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
25. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
26. A.D'Incecco, M.Andreozzi, V.Ludovini, E.Rossi, A.Capodanno, L.Landi, C.Tibaldi, G.Minuti, J.Salvini, E.Coppi, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015; 112:95-102; PMID:25349974; http://dx.doi.org/10.1038/bjc.2014.555
27. D.S.Chen, B.A.Irving, F.S.Hodi. Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012; 18:6580-7; PMID:23087408; http://dx.doi.org/10.1158/1078-0432.CCR-12-1362
28. J.C.Soria, C.Cruz, R.Bahleda, J.P.Delord, L.Horn, R.S.Herbst, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur J Cancer 2013; 49(suppl):abstract 3408
29. N.Chen, W.Fang, J.Zhan, S.Hong, Y.Tang, S.Kang, Y.Zhang, X.He, T.Zhou, T.Qin, et al. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol 2015; 10:910-23; PMID:25658629; http://dx.doi.org/10.1097/JTO.0000000000000500
30. W.A.Cooper, T.Tran, R.E.Vilain, J.Madore, C.I.Selinger, M.Kohonen-Corish, P.Yip, B.Yu, S.A.O'Toole, B.C.McCaughan, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 2015; 89:181-8; PMID:26024796; http://dx.doi.org/10.1016/j.lungcan.2015.05.007
31. B.Gao, Y.Sun, J.Zhang, Y.Ren, R.Fang, X.Han, L.Shen, X.Y.Liu, W.Pao, H.Chen, et al. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. J Thorac Oncol 2010; 5:1130-5; PMID:20559149; http://dx.doi.org/10.1097/JTO.0b013e3181e05016
32. N.C.Bae, M.H.Chae, M.H.Lee, K.M.Kim, E.B.Lee, C.H.Kim, T.I.Park, S.B.Han, S.Jheon, T.H.Jung, et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet 2007; 173:107-13; PMID:17321325; http://dx.doi.org/10.1016/j.cancergencyto.2006.10.007
33. S.Y.Lee, M.J.Kim, G.Jin, S.S.Yoo, J.Y.Park, J.E.Choi, H.S.Jeon, S.Cho, E.B.Lee, S.I.Cha, et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010; 5:1734-40; PMID:20881644; http://dx.doi.org/10.1097/JTO.0b013e3181f0beca
34. M.Suzuki, H.Shigematsu, K.Hiroshima, T.Iizasa, Y.Nakatani, J.D.Minna, A.F.Gazdar, T.Fujisawa. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 2005; 36:1127-34; PMID:16226114; http://dx.doi.org/10.1016/j.humpath.2005.08.007
35. R.J.Slebos, R.E.Kibbelaar, O.Dalesio, A.Kooistra, J.Stam, C.J.Meijer, S.S.Wagenaar, R.G.Vanderschueren, N.van Zandwijk, W.J.Mooi. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323:561-5; PMID:2199829; http://dx.doi.org/10.1056/NEJM199008303230902
36. E.B.Arribalzaga. New tumor, node, metastasis staging system for lung cancer. J Thorac Oncol 2009; 4:1301; author reply-2; PMID:20197739; PMID:24714771; http://dx.doi.org/10.1097/JTO.0b013e3181b5a867
37. J.M.Taube, A.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim, L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74.; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
38. S.Antonia, J.Grosso, C.Horak, C.Harbison, J.Kurland, D.Inzunza, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer treated with nivolumab. J Thorac Oncol 2013; 8(suppl):abstract P2.11-035
39. J.Grosso, C.E.Horak, D.Inzunza, D.M.Cardona, J.S.Simon, A.K.Gupta, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2013; 31(suppl):abstract 3016
40. J.C.Soria, C.Cruz, R.Bahleda, J.P.Delord, L.Horn, R.S.Herbst, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur J Cancer 2013; 49(suppl):abstract 3408
41. K.Lin, J.Cheng, T.Yang, Y.Li, B.Zhu. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-kappaB. Biochem Biophys Res Commun 2015; 463:95-101; PMID:25998384; http://dx.doi.org/10.1016/j.bbrc.2015.05.030
42. Y.Tang, W.Fang, Y.Zhang, S.Hong, S.Kang, Y.Yan, N.Chen, J.Zhan, X.He, T.Qin, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 2015; 6:14209-19; PMID:25895031; http://dx.doi.org/10.18632/oncotarget.3694
43. K.Azuma, K.Ota, A.Kawahara, S.Hattori, E.Iwama, T.Harada, K.Matsumoto, K.Takayama, S.Takamori, M.Kage, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014; 25:1935-40; PMID:25009014; http://dx.doi.org/10.1093/annonc/mdu242
44. Y.Zhang, L.Wang, Y.Li, Y.Pan, R.Wang, H.Hu, H.Li, X.Luo, T.Ye, Y.Sun, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014; 7:567-73; PMID:24748806; http://dx.doi.org/10.2147/OTT.S59959
45. E.A.Akbay, S.Koyama, J.Carretero, A.Altabef, J.H.Tchaicha, C.L.Christensen, O.R.Mikse, A.D.Cherniack, E.M.Beauchamp, T.J.Pugh, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3:1355-63; PMID:24078774; http://dx.doi.org/10.1158/2159-8290.CD-13-0310
46. C.Y.Yang, M.W.Lin, Y.L.Chang, C.T.Wu, P.C.Yang. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014; 50:1361-9; PMID:24548766; http://dx.doi.org/10.1016/j.ejca.2014.01.018